Total Health

 

Total Health is the largest provider of free cancer care resources for people who are treating or living with cancer. Our programs arm cancer care teams with the latest research and strategies to improve patient outcomes.

For more info visit our website at Total Health.

 

San Francisco
07:34

2020 ASCO Virtual Direct™ Highlights

Olaparib Efficacy in Recurrent Ovarian Cancer: Is There OS Improvement With Maintenance Olaparib in Platinum-Sensitive BRCA+ Patients?

FEATURING Oliver Dorigo
  • 35 views
  • February 2, 2021
06:58

2020 ASCO Virtual Direct™ Highlights

Early Stage HER2+ BC: How Effective Is Adjuvant Neratinib?

FEATURING Hope Rugo
  • 684 views
  • January 19, 2021
  • 2
11:36

2020 ASCO Virtual Direct™ Highlights

Treating Early Stage HER2+ BC: Which Patients Need New HER2-Targeted Agents?

FEATURING Hope Rugo
  • 349 views
  • January 19, 2021
  • 2
14:12

Total Health

HER2+ Targeted Agents for MBC: How to Best Sequence in Clinical Practice and Individualize Treatment Strategy?

FEATURING Hope Rugo
  • 884 views
  • January 12, 2021
  • 5
12:36

2020 ASCO Virtual Direct™ Highlights

HNSCC 2020 ASCO Trials Review: Can We Use a Gene Set to Predict Tumor Response in NPC? What Is the Link Between Abx Use and R/M HNSCC Patient Survival Treated With ICIs? Is Transoral Resection of p16+ OPC Safe and Promising Deintensification Approach?

FEATURING A. Colevas
  • 10 views
  • January 5, 2021
10:46

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on SCCHN: How to Dose Cisplatin With Radiation? Is There a Distinction Between Weekly & Monthly CDDP?

FEATURING A. Colevas
  • 10 views
  • January 5, 2021
09:35

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on HNSCC: Does OMC Improve Outcomes of Palliatively Treated Patients? Is SLN an Option for T1-2 N0 OC and OP SCCHN?

FEATURING A. Colevas
  • 7 views
  • January 5, 2021
25:25

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Social Media in Cancer Care: How to Utilize Social Media for Cancer Patient Education, and Improve Communication With Key Stakeholders?

FEATURING Deanna Attai
  • 2 views
  • December 22, 2020
11:26

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced HCC: Is Novel Tremelimumab/Durvalumab Regimen Active? What Is the ORR With 1L Lenvatinib and Pembro?

FEATURING Kit Wong
  • 22 views
  • December 4, 2020
06:33

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Resectable Pancreatic Ductal Adenocarcinoma: Is There a Difference Between Perioperative FOLFIRINOX vs. Gem / nab-P in Efficacy?

FEATURING Kit Wong
  • 14 views
  • December 4, 2020
07:07

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Resectable GE Adenocarcinoma: Does Perioperative FLOT/Ramucirumab Improve pCR Compared to FLOT?

FEATURING Kit Wong
  • 23 views
  • December 4, 2020
06:33

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ Esophageal Adenocarcinoma: Does the Addition of Trastuzumab to Trimodality Treatment Improve DFS?

FEATURING Kit Wong
  • 136 views
  • December 4, 2020
07:24

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Stage III CRC: Are Patients with Stage III Colon Cancer Well-Served With 3 Months of Chemotherapy?

FEATURING Chloe Atreya
  • 1,578 views
  • August 13, 2020
  • 11
06:09

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on BRAFV600E mCRC: How Effective Is FDA Approved 2L Encorafenib + Cetuximab?

FEATURING Chloe Atreya
  • 79 views
  • August 20, 2020
10:08

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ mCRC: Did Trastuzumab Deruxtecan Demonstrate Activity in Patients With HER2-Expressing Disease Who Are Refractory to Standard Therapies?

FEATURING Chloe Atreya
  • 133 views
  • August 20, 2020
  • 1
07:34

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Data on Pembro vs. Chemo in MSI-H mCRC: Is There a Clinically Meaningful and Statistically Significant Difference in PFS?

FEATURING Chloe Atreya
  • 94 views
  • August 20, 2020
18:34

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced Melanoma: Is PD-1 + Ipilimumab Superior to Ipilimumab Alone in Patients Resistant to PD-1 Therapy?

FEATURING Kevin Kim
  • 19 views
  • August 13, 2020
07:53

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced Melanoma: Does Adoptive TIL Therapy Have a Significant Impact on Patients Who Were Previously Treated With PD-1 Antibody?

FEATURING Kevin Kim
  • 70 views
  • August 20, 2020
10:11

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on V600 BRAF Melanoma: Is the Combination of BRAF-Targeting + CPIs More Effective Than Targeted Therapy Alone?

FEATURING Kevin Kim
  • 78 views
  • August 20, 2020
09:23

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Hodgkin Lymphoma: Pembro vs. Brentuximab Vedotin in Late Stage Disease - Which Option is Superior?

FEATURING David Maloney
  • 143 views
  • August 19, 2020
  • 1
08:34

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Waldenström Macroglobulinemia: Zanubrutinib vs. Ibrutinib - Which BTKi Option is Better?

FEATURING David Maloney
  • 332 views
  • August 18, 2020
  • 1
07:09

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on DLBCL: Venetoclax + Dose-Adjusted R-EPOCH - Did This Combination Show Activity in Richter’s Syndrome?

FEATURING David Maloney
  • 179 views
  • August 19, 2020
10:30

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on FL: Is CAR-T Axi-Cel Therapy a Promising Therapeutic Approach?

FEATURING David Maloney
  • 94 views
  • August 13, 2020
09:04

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Recurrent Ovarian Cancer: Does Secondary Cytoreductive Surgery Improve PFS and OS in Platinum Sensitive Disease?

FEATURING Oliver Dorigo
  • 9 views
  • August 18, 2020
04:17

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on GTT Resistant to Monochemotherapy: Should We Consider Avelumab a New Therapeutic Option?

FEATURING Oliver Dorigo
  • 57 views
  • August 18, 2020
07:21

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Post-Operative Adjuvant Therapy in Stage IB1 - IIA2 Cervical Cancer: Does SCRT Following Radical Hysterectomy Improve DFS vs. Radiation Alone/Concurrent Chemoradiation?

FEATURING Oliver Dorigo
  • 134 views
  • August 18, 2020
  • 1
06:49

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Recurrent Ovarian Cancer: Does the Addition of Mirvetuximab Soravtansine (MIRV) to Bevacizumab Have Promising Activity in FRα Platinum Agnostic Disease?

FEATURING Oliver Dorigo
  • 64 views
  • August 18, 2020
09:40

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on BC Adjuvant Therapy: What Is The Value of Early Local Therapy on Intact Primary Tumors in Patients With MBC?

FEATURING Mark Pegram
  • 267 views
  • August 18, 2020
08:49

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on BC Adjuvant Therapy: Is There a Role for Adjuvant Endocrine Therapy Combined With CDK4/6i in Early Stage Disease?

FEATURING Mark Pegram
  • 234 views
  • August 18, 2020
  • 1
06:25

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on BC Adjuvant Therapy: Has Anthracycline Finally Been Derailed in HER2+ EBC?

FEATURING Mark Pegram
  • 722 views
  • August 18, 2020
09:16

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ BC Adjuvant Therapy: Can We Substitute TDM-1 + Pertuzumab for Paclitaxel + Pertuzumab + Trastuzumab Following 4 Cycles of AC?

FEATURING Mark Pegram
  • 119 views
  • August 18, 2020
  • 1
10:52

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Adjuvant Therapy in TNBC: Is the Addition of Pembrolizumab Practice Changing? Does Maintenance Therapy w/ Metronomic Capecitabine Improve DFS?

FEATURING Mark Pegram
  • 1,775 views
  • August 13, 2020
  • 10
15:24

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HR+ MBC: Is There an Optimal Hormone Partner in the 1L Setting With CDK4/6i? Is There a Benefit to Alpelisib/Fulvestrant After Progression on CDKi?

FEATURING Hope Rugo
  • 235 views
  • August 19, 2020
  • 1
09:48

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on IO in mTNBC: Does TMB Impact the Clinical Outcome With Pembrolizumab vs. Chemotherapy?

FEATURING Hope Rugo
  • 771 views
  • August 26, 2020
  • 5
10:52

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on HER2+ MBC: Does Tucatinib Combined With Trastuzumab and Capecitabine Have the Potential to Become a New SoC?

FEATURING Hope Rugo
  • 489 views
  • August 13, 2020
  • 3
05:02

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on IO in mNSCLC: Can We Consider Combination of Nivo and Ipi, Together With a Limited Course of Chemotherapy a New 1L Treatment Option?

FEATURING Ravi Salgia
  • 557 views
  • August 7, 2020
  • 4
08:02

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on mUC: Can Tumor Microenvironment Biomarkers Help Predict Which Patients May Derive Greater Benefit from Upfront Anti-PD-L1 Therapy With Atezolizumab?

FEATURING David Quinn
  • 207 views
  • August 13, 2020
06:18

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced RCC: Is Nivo Monotherapy Active in Treatment Naive ccRCC?

FEATURING David Quinn
  • 74 views
  • August 24, 2020
09:35

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced RCC: 1L Pembro + Axitinib vs. Sunitinib - Which Option Has Superior and Durable Antitumor Activity?

FEATURING David Quinn
  • 330 views
  • August 13, 2020
  • 2
10:31

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Advanced Urothelial Cancer: Maintenance Avelumab + BSC vs BSC Alone - Does Avelumab 1L Maintenance Represent a Paradigm Shift for Clinical Practice?

FEATURING David Quinn
  • 170 views
  • August 13, 2020
09:43

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Delivery of ADT in Advanced Prostate Cancer: Relugolix vs. Leuprolide Acetate - Which Option Is Superior?

FEATURING Hala Borno
  • 120 views
  • August 24, 2020
08:38

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Molecular Imaging in Prostate Cancer: Is 18F-DCFPyL-PET/CT Superior to Standard Imaging in Men w/ BCR? Is 68Ga-PSMA-11 Accurate in Pelvic Nodal Metastasis Detection?

FEATURING Hala Borno
  • 121 views
  • August 24, 2020
  • 1
09:15

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on nmCRPC: Does the Utilization of Early AR Antagonism Prolong Survival?

FEATURING Hala Borno
  • 71 views
  • August 13, 2020
09:28

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on 1L IO in ES-SCLC: Is There a Benefit of Adding Pembro to EP? Is the Addition of Durvalumab to EP a New SoC Offering the Flexibility of Platinum Choice?

FEATURING Ravi Salgia
  • 345 views
  • August 13, 2020
  • 2
13:53

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Targeted Therapy in NSCLC: Is T-DXd a New Option for HER2+ Disease? Is Osimertinib Effective Enough in EGFRm Disease to Be Considered Practice Changing?

FEATURING Ravi Salgia
  • 272 views
  • August 13, 2020
  • 1